跳到正文
原文
The Lancet Oncology· Clare Turnbull, Sandra Perdomo, Susan Domchek, William D Foulkes, Paul Pharoah, Patricia Ashton-Prolla, Bhawna Sirohi, Joaquin Mateo, Hilary A Robbins, Richard Sullivan, Mark Lawler, Raffaella Casolino·· 2026-09-25AI 评分40

从遗传门诊走向普通人群:扩大癌症易感基因检测的政策启示

[Policy Review] Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population

AI 导读

癌症易感基因检测正从遗传专科门诊快速扩展至常规肿瘤诊疗和人群基因组项目,BRCA1、BRCA2、MLH1、MSH2 等首批基因的致癌风险已较明确,相关干预也有大量观察性证据支持,但尚缺乏随机试验。文章指出,大规模推广、尤其是对健康人群检测的实施速度已超过现有证据,需在获益、成本与危害之间重新权衡。

来源:The Lancet Oncology · thelancet.com